Nutex Health Inc. Reports 2025 Financial Results & Announces Second Stock Repurchase Program
Nutex Health Inc. Reports 2025 Financial Results & Announces Second Stock Repurchase Program
Key Highlights from 2025 Financial Report
- Total Revenue: Nutex Health Inc. reported total revenue of \$875.3 million for the full year 2025.
- Assets & Liquidity: As of December 31, 2025, the company held total assets of \$918.5 million, with cash and cash equivalents of \$185.6 million and net long-term debt of \$29.2 million.
- Net Income: The company recorded net income of \$180.4 million for 2025, a significant turnaround from a net loss of \$43.4 million in 2024.
- Earnings Per Share (EPS): Basic EPS for 2025 was \$9.69, compared to a loss per share of \$(10.39) in 2024.
- EBITDA: Earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at \$168.6 million for 2025, compared to \$98.8 million in 2024.
- Stock-based Compensation: The company reported a substantial increase in stock-based compensation, totaling \$117.0 million in 2025, up from \$16.6 million in 2024.
Fourth Quarter 2025 Performance
- Q4 Revenue Decline: Total revenue for the fourth quarter was \$151.7 million, down 41.1% from \$257.6 million in Q4 2024. The company attributed this decrease primarily to two factors:
- A reduction in volumes and reimbursement rates.
- Changes in payer mix.
- Q4 EBITDA: Fourth quarter EBITDA was \$25.7 million, compared to \$78.9 million in the same quarter of 2024.
- Q4 Stock-based Compensation: Stock-based compensation turned negative in Q4 2025, reported as \$(2.6) million, compared to \$14.6 million for Q4 2024.
Shareholder Updates & Price Sensitive Developments
-
Second Stock Repurchase Program Announced
The Board of Directors has authorized a second stock repurchase program of up to \$25.0 million over the next six months. This program aims to enhance shareholder value and offset dilution from the future issuance of shares related to stock compensation obligations for under-construction and ramping hospitals.
The timing and amount of repurchases will be at management’s discretion and may be affected by market and economic conditions, stock price, earnings, capital requirements, and other relevant factors. The program may be amended, suspended, or discontinued at any time.
-
Conference Call Details
Nutex Health will host a conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss fourth quarter and full-year results. Interested parties may dial 1-877-407-9208 or 1-201-493-6784 to participate.
-
Balance Sheet Developments
- Total equity increased to \$423.4 million as of December 31, 2025, up from \$188.5 million at year-end 2024.
- Accumulated deficit improved to \$(286.2) million from \$(357.0) million in the prior year.
- The company reported noncontrolling interests of \$94.0 million at year-end 2025, up from \$56.1 million in 2024.
-
Cash Flow Highlights
- Net cash provided by operating activities: \$168.6 million in 2025, up from \$98.8 million in 2024.
- Net cash used in investing activities: \$(11.2) million in 2025.
- Net cash used in financing activities: \$(97.9) million in 2025, compared to \$22.0 million provided in 2024.
-
Other Notable Items
- High Stock-Based Compensation: Investors should note the significant increase in stock-based compensation, which may affect dilution and future share price.
- Impairments: The company did not record any impairment of assets in 2025, compared to \$51.7 million in 2024.
- Legal and Regulatory Risks: The company highlighted ongoing regulatory and litigation uncertainties under the No Surprises Act, lawsuits with insurance providers, and other risks that could materially impact results.
Key Metrics Table (FY 2025 vs. 2024)
| Metric |
2025 |
2024 |
2023 |
| Total Revenue |
\$875.3 million |
Not stated |
Not stated |
| Net Income (Loss) |
\$180.4 million |
\$(43.4) million |
Not stated |
| EBITDA |
\$168.6 million |
\$98.8 million |
Not stated |
| EPS (Basic) |
\$9.69 |
\$(10.39) |
Not stated |
| Stock-based Compensation |
\$117.0 million |
\$16.6 million |
\$2.8 million |
| Total Assets |
\$918.5 million |
Not stated |
Not stated |
| Total Equity |
\$423.4 million |
\$188.5 million |
Not stated |
| Accumulated Deficit |
\$(286.2) million |
\$(357.0) million |
Not stated |
| Cash & Equivalents |
\$185.6 million |
Not stated |
Not stated |
| Long-term Debt, net |
\$29.2 million |
Not stated |
Not stated |
| Noncontrolling Interests |
\$94.0 million |
\$56.1 million |
Not stated |
Key Takeaways for Shareholders
- The return to profitability in 2025 and strong EBITDA growth are major positives for Nutex Health Inc.
- The significant decrease in Q4 revenue year-on-year could raise concerns about future growth and warrants closer scrutiny by investors.
- The \$25 million stock repurchase program is a potentially price-moving event, reflecting confidence in the company’s valuation and intention to offset dilution from stock compensation.
- Investors should closely monitor the increase in stock-based compensation and its impact on future dilution and share value.
- Ongoing regulatory and legal risks are highlighted and remain a potential overhang on the company’s valuation.
Disclaimer
This article is a summary and analysis of Nutex Health Inc.’s 2025 financial results and related shareholder news, based on the company’s official filings and press releases. It does not constitute investment advice. Investors should consult the full SEC filings and their financial advisors before making investment decisions. The company’s future performance may be materially affected by risks, uncertainties, and other factors as discussed in its filings with the Securities and Exchange Commission.
View Nutex Health, Inc. Historical chart here
